In an all-day hearing, the agency’s scientists argued against allowing broad access to unproven drugs that the agency had banned three years ago.
A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agenda
In an all-day hearing, the agency’s scientists argued against allowing broad access to unproven drugs that the agency had banned three years ago.
